{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:clemidsogene lanparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03584165: Phase 3 Interventional Enrolling by invitation Choroideremia
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04566445: Phase 2 Interventional Terminated Dry Age-related Macular Degeneration
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:domofenogene zalfaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04281485: Phase 3 Interventional Active, not recruiting Duchenne Muscular Dystrophy
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:peboctocogene camaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02716246: Phase 2/Phase 3 Interventional Recruiting MPS IIIA
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:inlezifigene civaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03612869: Phase 2/Phase 3 Interventional Unknown status Mucopolysaccharidosis Type IIIA
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:laruparetigene zovaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE